ESC 365 - The trv027 biased ligand of the angiotensin receptor study in acute heart failure (BLAST-AHF) trial: a phase IIb dose finding study.

HFA Premium Access

The trv027 biased ligand of the angiotensin receptor study in acute heart failure (BLAST-AHF) trial: a phase IIb dose finding study.

Session: Late Breaking Trials I: Focus on acute heart failure

Topic: Acute Heart Failure

Speaker: Professor G. Felker (Durham, US)

Event: HEART FAILURE 2016

Congress Presentation

Add to my library

About the speaker

Professor G Michael Felker

Duke University Medical Center, Durham (United States of America)

14 presentations

0 follower

12 more presentations in this session

Bi treatment with hydralazine/nitrates versus placebo in africans admitted with acute heart failure (BA-HEF).

Speaker: Professor K. Sliwa (Cape Town, ZA)

Discussion: BA-HEF.

RELAX-REPEAT: a multicentre, prospective, randomised, double-blind study evaluating the safety and tolerability of repeat doses of serelaxin in patients with chronic heart failure.

Speaker: Professor J. Teerlink (San Francisco, US)

Discussion: RELAX-REPEAT.

Positive hemodynamic effects of CXL-1427, a novel nitroxyl prodrug in advanced heart failure patients.

Speaker: Professor V. Mitrovic (Nauheim, DE)

Access the full session

Late Breaking Trials I: Focus on acute heart failure

Speakers: Professor G. Felker, Professor K. Sliwa, Professor J. Teerlink, Professor V. Mitrovic

About the event

HEART FAILURE 2016

21 May - 24 May 2016

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources